Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Gökbuget, N., . . . Advani, A. S. (2019). Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study. Cancer.
シカゴスタイル引用形Kantarjian, Hagop M., et al. "Inotuzumab Ozogamicin Versus Standard of Care in Relapsed or Refractory Acute Lymphoblastic Leukemia: Final Report and Long‐term Survival Follow‐up From the Randomized, Phase 3 INO‐VATE Study." Cancer 2019.
MLA引用形式Kantarjian, Hagop M., et al. "Inotuzumab Ozogamicin Versus Standard of Care in Relapsed or Refractory Acute Lymphoblastic Leukemia: Final Report and Long‐term Survival Follow‐up From the Randomized, Phase 3 INO‐VATE Study." Cancer 2019.